SG Americas Securities LLC Purchases Shares of 69,382 Olema Pharmaceuticals, Inc. $OLMA
SG Americas Securities LLC acquired a new stake of 69,382 shares in Olema Pharmaceuticals (NASDAQ:OLMA) during Q4, valued at approximately $1.735 million. This purchase represents about 0.10% ownership, alongside increased stakes from other institutional investors like Goldman Sachs. Olema Pharmaceuticals, with a market cap of $1.31 billion, holds a "Moderate Buy" consensus rating from analysts, targeting an average price of $44.40.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. announced that it granted stock options to four new employees to purchase an aggregate of 188,500 shares of the Company's common stock. These grants, effective April 1, 2026, were made under the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, have a 10-year term, and an exercise price of $15.12 per share.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (Olema Oncology) announced that it granted stock options to four new employees to purchase an aggregate of 188,500 shares of the Company's common stock. These grants were made under the Company's 2022 Inducement Plan and are in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years with an exercise price of $15.12 per share.
OLMA SEC Filings - Olema Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Olema Pharmaceuticals (OLMA) SEC filings, including annual, quarterly, and material event reports, along with insider trading forms. It features AI-powered summaries of these documents to help investors quickly understand key events, financial status, and clinical or collaboration updates. The article also lists recent filings, such as a major ownership stake reported by Bain Capital, the exit of Deep Track Capital, and several insider stock option awards and sales, providing detailed insights into the company's financial and operational activities.
OLMA Technical Analysis & Stock Price Forecast
Olema Pharmaceuticals Inc (OLMA) currently exhibits a "Sell" technical sentiment based on an analysis of 10 technical signals, with 4 indicators showing buy and 6 indicating sell. Key indicators like MACD and some moving averages suggest a selling trend, although the RSI is neutral. The stock is trading above its 200-day moving average, with identified resistance at $15.777 and strong support at $12.897.
A Look At Olema Pharmaceuticals (OLMA) Valuation After Earnings And New Shelf Registration Filing
Olema Pharmaceuticals (OLMA) is under scrutiny following its Q4 and full-year 2025 results, revealing significant net losses and a new shelf registration for up to US$71.82 million. Despite recent sharp declines in share price, the stock shows strong long-term returns and trades at a discount according to analyst targets and a Discounted Cash Flow model, suggesting a potential opportunity for investors. However, an unprofitable outlook and valuation swings warrant careful consideration of funding needs and execution risks.
Hennion & Walsh Asset Management Inc. Increases Position in Olema Pharmaceuticals, Inc. $OLMA
Hennion & Walsh Asset Management Inc. significantly increased its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 83.2% in the fourth quarter to 447,046 shares, valued at approximately $11.18 million. Institutional investors now own 91.78% of the company, and Wall Street analysts maintain a largely bullish outlook with a "Moderate Buy" rating and an average price target of $44.40. Despite institutional confidence, insiders have recently sold over 217,000 shares, though they still retain a 16.36% ownership.
Wolfe Research initiates coverage of Olema Pharmaceuticals (OLMA) with peer perform recommendation
Wolfe Research has initiated coverage of Olema Pharmaceuticals (OLMA) with a "Peer Perform" recommendation. This new coverage suggests the firm sees OLMA's stock performance likely to align with its industry peers.
Wolfe Research Initiates Coverage on Olema Pharmaceuticals (NASDAQ:OLMA)
Wolfe Research initiated coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a "peer perform" rating, while other analysts maintain a "Moderate Buy" consensus. The company, a clinical-stage biopharma with a lead drug in Phase 3 for breast cancer, saw significant insider share sales totaling approximately $5.97 million in the last quarter. Despite this, institutional investors substantially increased their holdings in Q4, indicating mixed sentiment towards the stock.
Olema Pharmaceuticals seeks senior director to lead accounting operations and financial reporting
Olema Pharmaceuticals is actively searching for a Senior Director of Accounting and Assistant Controller to strengthen its financial operations and ensure accurate reporting. This recruitment highlights the company's dedication to financial integrity as it expands within the biotech sector. The new hire will oversee key accounting functions, supporting Olema's ongoing growth and recent financial disclosures.
Jim Cramer on Olema Pharmaceuticals: “Too Risky for Me”
Jim Cramer advised against investing in Olema Pharmaceuticals (NASDAQ: OLMA), calling it "too risky" for the current market due to the potential for significant financial loss. Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on women's cancers, reported a Q4 2025 GAAP EPS of -$0.50, exceeding estimates, but saw its net loss for FY25 increase to $162.5 million. Insider Monkey suggests that while OLMA carries risk and potential, AI stocks may offer higher returns in a shorter timeframe.
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?
Paradigm Biocapital Advisors LP significantly increased its stake in Olema Pharmaceuticals (NASDAQ:OLMA) during Q4 2025, adding 750,000 shares for an estimated $13.35 million. This boosted their position to $122.09 million, representing 4.5% of their AUM. Despite Olema's stock soaring 242% over the past year, the company holds promising prospects with over $500 million in cash, a recent $200 million capital raise, and upcoming Phase 3 data and pipeline readouts.
Invus entities disclose 4.5% stake in Olema (OLMA) on Schedule 13G
Invus entities have disclosed a 4.5% stake in Olema Pharmaceuticals (OLMA) via a Schedule 13G filing. This filing indicates that Invus Public Equities directly holds 3,898,500 shares and Avicenna Life Sci Master Fund holds 563,449 shares as of March 16, 2026. The disclosure states that the holdings were not acquired for the purpose of changing or influencing control of the issuer.
Olema Pharmaceuticals (OLMA) loses 33.4% in 4 weeks, here's why a trend reversal may be around the corner
This article from Zacks.com suggests a potential trend reversal for Olema Pharmaceuticals (OLMA) despite a recent 33.4% loss over four weeks. The analysis points to the company's strong fundamentals and positive estimate revisions as key indicators that the stock may be undervalued and poised for a rebound. Investors are encouraged to consider these factors as signs of an impending upward movement.
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Olema Oncology announced it will present two preclinical posters at the 2026 AACR Annual Meeting in San Diego. The presentations will detail preclinical data for palazestrant, a complete estrogen receptor antagonist (CERAN), and OP-3136, a KAT6 inhibitor, specifically their mechanisms of action and synergistic effects. These studies highlight Olema's pipeline advancements in targeted therapies for breast cancer.
Olema Pharmaceuticals (OLMA) Is Down 6.7% After Posting Wider Losses And Filing New Stock Shelf
Olema Pharmaceuticals (OLMA) recently reported wider annual losses for Q4 2025 but showed a slightly improved per-share result and a significant cash balance of US$505.4 million. The company also filed a new US$71.82 million shelf registration for common stock and continues to advance its breast cancer pipeline. Shares dropped 6.7% following the announcement, and the stock may still be overvalued by 22% according to Simply Wall St.
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
JPMorgan Chase & Co. has raised its price target for Olema Pharmaceuticals (NASDAQ:OLMA) from $55 to $58, maintaining an "overweight" rating and suggesting a substantial potential upside of 304%. Despite this optimistic forecast, the stock recently traded down 4.7% to $14.36, and insider selling totaling over $23 million over the past 90 days indicates mixed sentiment. Other analysts offer varied ratings, with the consensus being a "Moderate Buy" and an average price target of $44.89.
Olema Pharmaceuticals (OLMA) Drops 33.4% Over Past Month, Reasons Suggest a Potential Turnaround Ahead
Olema Pharmaceuticals (OLMA) has seen its share price drop 33.4% in the last month, but technical and fundamental indicators suggest a potential rebound. The stock's Relative Strength Index (RSI) is in oversold territory at 27.66, signaling that selling pressure might be easing. Additionally, analysts have raised earnings estimates for OLMA, leading to a 1.1% increase in the consensus EPS forecast, and the company holds a Zacks Rank #2 (Buy).
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced it will present two preclinical posters at the 2026 AACR Annual Meeting in San Diego, California. The presentations will detail preclinical data for palazestrant (OP-1250), a complete estrogen receptor antagonist (CERAN), and OP-3136, a KAT6 inhibitor, showcasing their mechanisms of action and synergistic effects in breast cancer models. Both compounds are part of Olema's pipeline of targeted therapies for breast cancer, with palazestrant currently in Phase 3 clinical trials and OP-3136 in a Phase 1 study.
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced it will present two preclinical posters at the 2026 AACR Annual Meeting. The presentations will detail findings on palazestrant, a complete estrogen receptor antagonist (CERAN), and OP-3136, a KAT6 inhibitor, highlighting their mechanisms and synergistic effects in combating breast cancer. Olema Oncology is focused on developing targeted therapies for breast cancer, with palazestrant currently in Phase 3 trials and OP-3136 in a Phase 1 clinical study.
Lab study: Olema drug duo hits cancer growth and spread genes
Olema Oncology will present preclinical data for its drugs, palazestrant and OP-3136, at the 2026 AACR Annual Meeting. The studies indicate that palazestrant effectively antagonizes ERα, and in combination with OP-3136, it synergistically reduces gene signatures associated with cell proliferation and metastasis. This news has led to a double-digit price gain for OLMA stock, confirming recent positive market reactions to the company's progress and strengthening balance sheet.
Citigroup Forecasts Strong Price Appreciation for Olema Pharmaceuticals (NASDAQ:OLMA) Stock
Citigroup has raised its price target for Olema Pharmaceuticals (NASDAQ:OLMA) to $62 from $60, maintaining a "buy" rating and suggesting a significant upside of over 300%. Despite this analyst confidence and a "Moderate Buy" consensus, the stock recently traded down 8.8% to $15.14 and remains unprofitable. Insider selling has been substantial, with over $23 million worth of shares sold in the past 90 days, though insiders still hold 16.36% and institutions own 91.78% of the company.
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 5.2% Following Analyst Downgrade
Olema Pharmaceuticals (NASDAQ:OLMA) experienced a 5.2% stock drop after Guggenheim lowered its price target from $40 to $38, although maintaining a "buy" rating. The stock closed at $15.7360 on Tuesday with exceptionally low trading volume. Despite this downgrade and significant insider selling, the overall analyst consensus remains a "Moderate Buy" with a $43.00 target price.
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Olema Pharmaceuticals, Inc. announced it will present two preclinical posters at the American Association for Cancer Research (AACR) Annual Meeting in April 2026. The presentations will detail preclinical data for palazestrant, a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), and OP-3136, a KAT6 inhibitor. These presentations will highlight palazestrant's mechanism of action and the synergistic effects of combining palazestrant with OP-3136.
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Olema Oncology reported its financial and operating results for the fourth quarter and full year ended December 31, 2025, highlighting significant advancements in its clinical trials for palazestrant and OP-3136. The company secured $218.5 million in gross proceeds from a public offering, bolstering its cash reserves to $505.4 million, and is preparing for a potential commercial launch in late 2027. Key upcoming milestones include top-line data from the pivotal Phase 3 OPERA-01 trial and initial clinical results for OP-3136 in 2026.
Olema Pharmaceuticals (OLMA) Stock Jumps 9% Following Fourth Quarter Earnings Surprise
Olema Pharmaceuticals (OLMA) stock rose 8.5% after reporting a Q4 earnings beat, posting a loss of $0.50 per share against an anticipated $0.51. Despite concerns over Roche's recent persevERA trial failure, which could impact Olema's OPERA-02 trial, analysts like Stifel maintain a bullish stance with a $48 price target due to the company's strong cash reserves extending to mid-2028. The stock has been volatile, with a 234% gain over the past year but a 41% drop year-to-date before this rally.
Olema Pharmaceuticals (OLMA) Stock Rises 9% After Q4 Earnings Beat
Olema Pharmaceuticals (OLMA) stock rose 8.5% after beating Q4 EPS estimates by $0.01, reporting a loss of $0.50 per share. Despite the beat, the company posted significant GAAP net losses for the quarter and full year 2025. Stifel reiterated its Buy rating with a $48 price target, citing a cash runway into mid-2028, although concerns remain following Roche's failed persevERA trial, which could impact Olema's OPERA-02 trial outlook.
[144] Olema Pharmaceuticals, Inc. SEC Filing
Olema Pharmaceuticals, Inc. (OLMA) has filed a Form 144 SEC filing, indicating an intended sale of 100,000 shares of common stock by insider Shane W. Kovacs. This sale, pursuant to an option granted in 2023, is noted for March 16, 2026, and follows several other large dispositions by Kovacs within the past three months. The filing details these transactions and outlines the standard regulatory information required for such insider sales.
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Olema Oncology will present two preclinical posters at the 2026 AACR Annual Meeting in April, highlighting data for palazestrant and OP-3136. Palazestrant, a CERAN and SERD, will show its ability to recruit the corepressor protein NCoR1, leading to complete antagonism of estrogen receptor alpha. The company will also present on the synergistic effects of palazestrant in combination with OP-3136, a KAT6 inhibitor, in downregulating cell proliferation and metastasis-related gene signatures.
Olema Pharmaceuticals (OLMA) Reports Q4 Earnings Beat
Olema Pharmaceuticals (OLMA) announced its Q4 GAAP EPS of -$0.50, surpassing expectations by $0.01. The clinical-stage biopharmaceutical company maintains a strong cash position of $505.4 million, focusing on developing targeted therapies for women's cancers despite currently reporting no revenue. The investment profile is complex, showing strong liquidity and promising drug candidates balanced against sector volatility and regulatory risks.
Olema Pharmaceuticals Inc (OLMA) announced that patient recruitment for the Phase 1 clinical study of its candidate drug OP-3136 is underway.
Olema Pharmaceuticals Inc (OLMA) has initiated patient recruitment for the Phase 1 clinical study of its drug candidate OP-3136. The company anticipates releasing preliminary data from this study in the second quarter of 2026. This announcement highlights progress in the development of OP-3136.
854,000 Shares in Olema Pharmaceuticals, Inc. $OLMA Acquired by Kingdon Capital Management L.L.C.
Kingdon Capital Management L.L.C. recently acquired 854,000 shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA), representing a new stake valued at approximately $8.36 million and a 1.24% ownership. Despite recent insider selling, analyst sentiment remains positive with a "Moderate Buy" consensus and an average price target of $41.00. Other hedge funds have also adjusted their positions in Olema Pharmaceuticals, and the company recently topped its EPS estimates.
Olema 10-K: $0 Revenue, $(1.87) EPS and $(162.5)M Net Loss
Olema reported zero product revenue and a net loss of $162.5 million for the year, primarily due to $178.7 million in operating expenses as it advances clinical-stage programs. The company's net loss per share was $(1.87), reflecting increased R&D and clinical trial spending without any commercially approved products. Olema expects its current cash and marketable securities to fund operations through mid-2028, supporting its planned clinical activities.
Olema Oncology (NASDAQ: OLMA) boosts cash as 2025 loss widens on R&D
Olema Oncology reported its financial and operating results for Q4 and full-year 2025, highlighting progress in its breast cancer pipeline and a strengthened balance sheet. The company raised approximately $218.5 million through a public offering, ending 2025 with $505.4 million in cash, despite a wider net loss of $162.5 million for the year due to increased R&D and corporate expenses. Olema anticipates key clinical milestones in 2026, including initial data for OP-3136 and top-line results from the Phase 3 OPERA-01 trial for palazestrant, preparing for a potential commercial launch in late 2027.
HighVista Strategies LLC Acquires 158,749 Shares of Olema Pharmaceuticals, Inc. $OLMA
HighVista Strategies LLC significantly increased its holdings in Olema Pharmaceuticals (OLMA) by 57.0%, acquiring an additional 158,749 shares. This makes Olema Pharmaceuticals the 22nd largest position in HighVista's portfolio. Despite this institutional buying, corporate insiders have been net sellers, disposing of over 800,000 shares recently, while analysts maintain a "Moderate Buy" rating with an average target price of $41.00.
Pier Capital LLC Has $5.13 Million Holdings in Olema Pharmaceuticals, Inc. $OLMA
Pier Capital LLC significantly reduced its stake in Olema Pharmaceuticals (NASDAQ:OLMA) by 32.0% in the third quarter, now holding 524,249 shares valued at $5.13 million. Despite this, institutional investors collectively own 91.78% of the company's stock, while insiders sold approximately $23.0 million worth of shares last quarter but still retain 16.36% ownership. Analysts generally hold a "Moderate Buy" rating for Olema Pharmaceuticals, with an average price target of $41.00.
Assessing Olema Pharmaceuticals (OLMA) Valuation After Breast Cancer Trial Setback Hits Sector Sentiment
Olema Pharmaceuticals' stock (OLMA) dropped sharply after a breast cancer drug trial setback in the sector, prompting a re-evaluation of its valuation. While a discounted cash flow (DCF) model suggests the company is significantly undervalued at $25.48 per share compared to its current $15.61, indicating strong future cash flow potential, its high Price-to-Book ratio of 4x (compared to the industry average of 2.7x) raises concerns given it is still pre-revenue and loss-making. Investors are advised to consider both the potential and the inherent risks of this clinical-stage biotech.
Assessing Olema Pharmaceuticals (OLMA) Valuation After Breast Cancer Trial Setback Hits Sector Sentiment
Olema Pharmaceuticals (OLMA) has seen its stock drop significantly after a setback in Roche's breast cancer trial, raising concerns about estrogen receptor targeted therapies. Despite recent declines, the company's valuation using a Discounted Cash Flow (DCF) model suggests it is undervalued at $25.48 per share against a market price of $15.61, indicating strong future cash flow potential. However, its high Price-to-Book (P/B) ratio of 4x, compared to the industry average of 2.7x, presents a more cautious outlook given that the company is currently loss-making and pre-revenue, highlighting dependence on successful clinical trials and future funding.
Insider sales at OLMA (NASDAQ: OLMA) include 241,999-share block in March
An insider at Olema Pharmaceuticals (NASDAQ: OLMA) filed a Form 144, proposing to sell 50,000 shares of common stock. This filing also disclosed multiple prior dispositions by Shane W. Kovacs, including a significant sale of 241,999 shares on March 9, 2026, and other transactions between January and March 2026. The Form 144 details cash proceeds from these insider sales and identifies Fidelity Brokerage Services as a broker involved.
Does Olema Pharmaceuticals (OLMA) Still Stand Apart After Roche’s Breast Cancer Trial Setback?
Olema Pharmaceuticals' stock faced a significant sell-off following Roche's failed breast cancer trial, raising questions about estrogen receptor-targeting drugs. Despite this, Olema's palazestrant program, in Phase 3 trials and developed with Pfizer and Novartis, has a differentiated profile. The article discusses Olema's investment narrative, highlighting its lack of revenue and ongoing losses, but also its strengthened cash position and analyst optimism.
Does Olema Pharmaceuticals (OLMA) Still Stand Apart After Roche’s Breast Cancer Trial Setback?
Olema Pharmaceuticals' stock dropped 41% after Roche's giredestrant breast cancer trial failed, raising concerns for estrogen receptor-targeting drugs. While Olema's palazestrant program is still in earlier Phase 3 trials, its financial position and analyst optimism offer some short-term stability despite ongoing losses and perceived increased risk for the drug class. Investors are advised to consider a wide range of valuations and risks before making an investment decision due to the uncertainty surrounding the long road to commercialization.
Olema Pharmaceuticals (OLMA) Stock Plummets 41% on Roche Trial Disappointment
Olema Pharmaceuticals (OLMA) stock dropped 41% after Roche's Phase 3 breast cancer trial for giredestrant failed to meet its primary endpoint, despite Olema's independent drug development program. Analysts at Stifel view this market overreaction as a potential buying opportunity for long-term investors, citing palazestrant's promising characteristics and the possibility it could become a pioneering therapy in first-line metastatic breast cancer treatment by 2028.
Oppenheimer, Cowen, H.C. Wainwright Maintain Buy/Outperform on OLMA March 2026
Three prominent analyst firms—Oppenheimer, Cowen & Co., and H.C. Wainwright—reaffirmed their positive ratings on Olema Pharmaceuticals, Inc. (OLMA) on March 9, 2026, with Oppenheimer maintaining Outperform and the others upholding Buy ratings. This continued conviction comes despite intraday share price drops following news, indicating sustained belief in OLMA's clinical pipeline, particularly for its Pala asset. H.C. Wainwright did, however, lower its price target to $38, a move suggesting more conservative near-term financial modeling.
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down Following Analyst Downgrade
Olema Pharmaceuticals (NASDAQ:OLMA) experienced a significant share price drop after HC Wainwright lowered its price target from $45 to $38. Despite the downgrade, analyst sentiment remains largely positive with a "Moderate Buy" consensus. Insider transactions show substantial selling, with 805,501 shares worth approximately $23.0 million sold in the last 90 days.
Olema Pharmaceuticals Faces Strategic Shifts Amid Market Turbulence
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) saw its stock drop by 16.19% due to increasing market pessimism and mixed financial performance. The company faces challenges with negative return on assets and equity but has a healthy short-term financial position and cash flow, suggesting a potential for strategic recalibration. Investors are keenly watching Olema's strategic adjustments to see if they can translate into a robust comeback and positive growth.
Olema Pharmaceuticals (NASDAQ: OLMA) CLO nets 40,000-share stock sale
Olema Pharmaceuticals' Chief Legal Officer, Mitchell Shawnte, exercised options for 40,000 shares of common stock at $4.37 per share and subsequently sold all 40,000 shares in open-market transactions on March 3-4, 2026, at weighted average prices in the mid-$20s. Following these transactions, Shawnte holds no directly owned common shares but retains 410,000 outstanding stock options. The transactions were disclosed in an SEC Form 4 filing.
Why Is Olema Pharmaceuticals Stock Dropping On Monday?
Olema Pharmaceuticals stock is dropping after Roche Holdings AG's phase 3 breast cancer study of giredestrant, a drug similar to Olema's lead candidate Palazestrant, did not meet its primary objective. Despite this, analysts maintain a "Buy" rating for OLMA, with an average price target of $37.33, and the stock had strong long-term performance over the past year.
Shawnte Mitchell Sells 15,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock
Shawnte Mitchell, an insider at Olema Pharmaceuticals (NASDAQ:OLMA), recently sold a total of 40,000 shares across two transactions on March 3rd and March 4th, totaling over $950,000. Following these sales, OLMA's stock dropped 7.3% to $22.56, though analysts largely maintain "Buy" ratings with an average target price of $41.78, and institutional investors hold a significant portion of the shares. The company, valued at $1.55 billion, is focused on developing therapies for women's cancers, with its lead candidate OP-1250 in Phase 3 clinical trials.
Olema Pharmaceuticals (NASDAQ:OLMA) Insider Shawnte Mitchell Sells 25,000 Shares
Olema Pharmaceuticals (NASDAQ:OLMA) insider Shawnte Mitchell sold a total of 40,000 shares of the company's stock across two transactions on March 3rd and 4th, totaling $951,400. Despite these insider sales, analysts generally maintain a "Moderate Buy" rating for OLMA with a consensus price target of $41.78, and several institutional investors have recently increased their holdings in the company. Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on therapies for women's cancers, with its lead product candidate, OP-1250, currently in Phase 3 clinical trials.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced the grant of stock options to four new employees to purchase an aggregate of 205,000 shares of common stock, effective March 2, 2026. These inducement grants were made under the Company's 2022 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest over four years, have a 10-year term, and an exercise price of $24.02 per share.
